OBJECTIVE: To evaluate the effect of ultrasound interventional injection of cisplatin in the treatment of hepatocellular carcinoma (HCC). METHODS:68 patients with HCC admitted to our hospital from February 2016 to February 2018 were enrolled. According to the different treatment methods, they were divided into a study group and a control group. The control group was treated with hepatic artery embolization chemotherapy (n=34), the study group adopted interventional ultrasound injection of cisplatin (n=34). The clinical treatment effects of the two groups of patients were compared; the liver function and the occurrence of adverse reactions were compared; all patients were followed up for 24 months, and their progressive-free survival (PFS) was also compared. RESULTS: The study group had higher total effective rate compared with the control group (91.18% vs 67.65%) (P<0.05); the AST, ALT, T-BIL and D-BIL levels of the two groups decreased remarkably after treatment, and the reduction in the study group was more obvious (P<0.05); the levels of VEGF, AFP and CEA of the two groups reduced noticeably after treatment, and the decrease in the study group was more significant (P<0.05); the total incidence of adverse reactions in the study group and the control group was 2.94% and 23.53% respectively, (P<0.05); the two groups were followed up for 24 months, and the disease control rate (DCR) of the control group was 58.82%, significantly lower than 85.29% in the study group; the PFS time of the control group was (15.68±4.23) lower than that of the study group (18.12±5.42) (P<0.05). CONCLUSION:Interventional ultrasound injection of cisplatin in the treatment of HCC has a definite effect. It can effectively relieve liver damage, reduce adverse reactions, improve serum tumor marker levels, and boost the DCR and PFS time of tumor patients. AJTR
RCT Entities:
OBJECTIVE: To evaluate the effect of ultrasound interventional injection of cisplatin in the treatment of hepatocellular carcinoma (HCC). METHODS: 68 patients with HCC admitted to our hospital from February 2016 to February 2018 were enrolled. According to the different treatment methods, they were divided into a study group and a control group. The control group was treated with hepatic artery embolization chemotherapy (n=34), the study group adopted interventional ultrasound injection of cisplatin (n=34). The clinical treatment effects of the two groups of patients were compared; the liver function and the occurrence of adverse reactions were compared; all patients were followed up for 24 months, and their progressive-free survival (PFS) was also compared. RESULTS: The study group had higher total effective rate compared with the control group (91.18% vs 67.65%) (P<0.05); the AST, ALT, T-BIL and D-BIL levels of the two groups decreased remarkably after treatment, and the reduction in the study group was more obvious (P<0.05); the levels of VEGF, AFP and CEA of the two groups reduced noticeably after treatment, and the decrease in the study group was more significant (P<0.05); the total incidence of adverse reactions in the study group and the control group was 2.94% and 23.53% respectively, (P<0.05); the two groups were followed up for 24 months, and the disease control rate (DCR) of the control group was 58.82%, significantly lower than 85.29% in the study group; the PFS time of the control group was (15.68±4.23) lower than that of the study group (18.12±5.42) (P<0.05). CONCLUSION: Interventional ultrasound injection of cisplatin in the treatment of HCC has a definite effect. It can effectively relieve liver damage, reduce adverse reactions, improve serum tumor marker levels, and boost the DCR and PFS time of tumorpatients. AJTR
Authors: Liang Yin; Jin Wang; Feng-Chang Huang; Yun-Fei Zhang; Ning Xu; Zheng-Qi Wen; Wen-Liang Li; Jian Dong Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2017-03-20